BioSpace News Archive

The telerehabilitation system is for patients who live far from actual centers of rehabilitation. It also decreases the regular visits of patients to hospitals and rehabilitation facilities, since, after discharge, doctors are likely to follow up with clients.

Drug discovery services market is slated to witness strong growth prospects in the global market, reaching an estimation of US$ 16,800.1 million in terms of revenue by 2026 end, according to a new study by Fact.MR.

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells.

GenSight Biologics announced that the journal of the American Academy of Ophthalmology, Ophthalmology®, has published results from the RESCUE pivotal Phase III clinical trial of LUMEVOQ® gene therapy in ND4 Leber Hereditary Optic Neuropathy subjects.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced that it has raised EUR 127 million in Series B financing.

The Fertility Partners, Canada’s leading platform of fertility practices, announced the acquisition of The Toronto Institute For Reproductive Medicine and ReproMed.

AuraVax Therapeutics Inc. (www.auravax.com), a biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, today announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists

HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”) to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Kim A. Keck has been appointed to its Board of Directors,